This treatment strategy, applied to HNSCC or breast cancer cells, activates a SMAD2/3/4-dependent transcriptional pathway that reestablishes TGFβ signaling, leading to an anti-proliferative effect. Here, TGFB1 is linked to head and neck squamous cell carcinoma.